Like Canopy Growth (TSX:WEED)? This Pot Stock Is Even Better

Hexo Corp (TSX:HEXO)(NYSE:HEXO) has all the advantages of Canopy Growth Corp (TSX:WEED)(NYSE:CGC), without the premium valuation.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canopy Growth (TSX:WEED)(NYSE:CGC) is a favourite among cannabis investors. With a $10.3 billion market cap, the stock is priced above nearly every competitor. One of the biggest reasons for this valuation is Canopy’s partnership with Constellation Brands.

With a $40 billion valuation, Constellation is an industry heavyweight, too. But instead of pot, Constellation is focused on alcohol. Last year, it was one of the largest alcoholic beverage distributors in North America, controlling renowned brands such as Corona, Robert Mondavi, Modelo, and dozens more.

When the marijuana bull market started gaining steam, Constellation invested billions into Canopy, making it one of the best-capitalized companies in the industry. The market is clearly pricing in future help, possibly in the form of a major distribution deal. Ultimately, many investors are wagering that Constellation will completely acquire Canopy, likely at a premium price.

It’s easy to connect the dots here. The cannabis market is eventually expected to be worth well more than $100 billion. Global alcohol sales, meanwhile, already surpass $1 trillion. With Constellation’s help, Canopy can dominate the next big thing in pot: cannabis-infused beverages.

But you’d be mistaken to believe the Constellation-Canopy tie-up is the only way to bet on this opportunity. There’s a much smaller company, with significantly more upside, that is ready to surprise the entire market.

Platform or bust

Over the last year or two, cannabis companies have been scrambling to ramp raw cannabis output. Armed with massive grow facilities, these firms are either selling it directly to the market or attempting to brand their production to create customer loyalty. From the beginning, Hexo (TSX:HEXO)(NYSE:HEXO) forged a different path.

Instead of competing directly with every other pot company, Hexo opted to launch the industry’s first pot platform. That is, Hexo would provide the base infrastructure for external partners to build on top of.

Let’s look at a real example.

As mentioned, cannabis-infused beverages will be the next big thing in pot. It has the potential to double or triple the entire market. This opportunity caught the eye of Molson Coors Canada, one of the most well-known brands in Canada.

To tap the opportunity, Molson would need to spend millions, if not billions of dollars scaling its own infrastructure. As with most large companies, it wasn’t willing to bet its future on a single emerging market. So, instead, Molson looked for partners. With its exclusive partnership with Constellation, Canopy isn’t a candidate for would-be partners like this.

Ultimately, Molson chose Hexo. Hexo already has the grow facilities, research and development capabilities, and packaging and distribution centres necessary to scale up a new product quickly and cheaply. No other pot company has the infrastructure that allows any global brand to spin-up pot products this efficiently.

This month, Molson and Hexo expect to release their first cannabis-infused beverages in Canada, beating nearly every competitor to market. With the Molson brand behind it, these products should gain market share quickly.

The true magic of Hexo is that it can replicate this partnership dozens of times. Other pot stocks can only accommodate a single partner. Stocks like Canopy can’t bring on any new partners, at least at this scale.

If you want as much upside as possible, choose the only cannabis stock that can take advantage of every opportunity and partner available: Hexo.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends Constellation Brands, HEXO., and HEXO. Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »